Previous 10 | Next 10 |
Stoke Therapeutics (NASDAQ: STOK ): Q3 GAAP EPS of -$0.26 beats by $0.02 . More news on: Stoke Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today reported financial results for the third quarter of 2019. “Our successful IPO has put us in a...
InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most im...
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today announced that Chief Executive Officer Edward M. Kaye, M.D., will present at two investor conferen...
InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most im...
No one who shares a delusion ever recognizes it as such .”― Sigmund Freud Stocks hit an all-time high this week for the first time since July. The Federal Reserve cut interest rates for a third time as expected on Wednesday. On Friday, the October Jobs report came in much...
Shares of Stoke Therapeutics (NASDAQ: STOK) crashed 42.6% in September, according to data provided by S&P Global Market Intelligence . That was a dramatic turnaround for the young biotech , which just had its IPO in June. August's story was dramatically different....
Seven biotech companies with initial valuations north of $1 billion began trading during the first nine months of 2019. Overall, these companies performed well. Their average and median returns were 13% and 14% respectively. In comparison, the SPDR S&P 500 ETF (NYSEARCA: SPY) and the Fide...
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced that Chief Executive Officer Edward M. Kaye, M.D., will present at the 2019 Cantor Global Healt...
Gainers: Alder BioPharmaceuticals (NASDAQ: ALDR ) +84% . SemGroup Corporation (NYSE: SEMG ) +63% . Yuma Energy (NYSEMKT: YUMA ) +63% . Wins Finance Holdings (NASDAQ: WINS ) +55% . Whiting Petroleum Corporation (NYSE: WLL ) +43% . New Concept Energy (NYSEMKT: GBR ) +34% . Califo...
News, Short Squeeze, Breakout and More Instantly...
Stoke Therapeutics Inc. Company Name:
STOK Stock Symbol:
NYSE Market:
Stoke Therapeutics Inc. Website:
2024-06-16 20:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the following upcoming investor conferences: Goldma...
2024-05-16 08:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...